Zydus Lifesciences Limited submitted a regulatory disclosure to BSE Limited and National Stock Exchange of India Limited regarding the closure of a USFDA inspection at its UK subsidiary, LiqMeds.
The US Food and Drug Administration (USFDA) conducted an inspection at LiqMeds, UK from November 9, 2026 to November 13, 2026. The inspection concluded with 4 observations. The company stated it will closely work with the USFDA to address these observations expeditiously.